While the concept of reactivating tumor suppressor proteins has been appreciated as a potential anti-cancer therapeutic strategy for decades, progress in developing therapies that target tumor suppressor proteins has lagged behind the successful development of therapies targeting oncoproteins such as protein kinases. This evidence concerns the gene TCHP and cancer.